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ABSTRACT 
Background: The two-stage Total Laparoscopic Hysterectomy (TLH) versus Total 
Abdominal Hysterectomy (TAH) for stage I endometrial cancer (LACE) randomised 
controlled trial was initiated in 2005. The primary objective of stage 1 was to assess whether 
TLH results in equivalent or improved QoL up to 6 months after surgery compared to TAH. 
The primary objective of stage 2 was to test the hypothesis that disease-free survival at 4.5 
years is equivalent for TLH and TAH.  Results addressing the primary objective of stage 1 of 
the LACE trial are presented here.  
Methods: The first 361 LACE participants (TAH n= 142, TLH n=190) were enrolled in the 
QoL substudy at 19 centres across Australia, New Zealand and Hong Kong, and 332 
completed the QoL analysis. Randomisation was performed centrally and independently from 
other study procedures via a computer generated, web-based system (providing concealment 
of the next assigned treatment) using stratified permuted blocks of 3 and 6, and assigned 
patients with histologically confirmed stage 1 endometrioid endometrial adenocarcinoma and 
ECOG performance status <2 to TLH or TAH stratified by histological grade and study 
centre. No blinding of patients or study personnel was attempted. QoL was measured at 
baseline, 1 and 4 weeks (early), and 3 and 6 months (late) after surgery using the Functional 
Assessment of Cancer Therapy-General (FACT-G) questionnaire. The primary endpoint was 
the difference between the groups in QoL change from baseline at early and late time points 
(a 5% difference was considered clinically significant). Analysis was performed according to 
the intention-to-treat principle using generalized estimating equations on differences from 
baseline for the early and late QoL recovery. The LACE trial is registered with 
clinicaltrials.gov (NCT00096408) and the Australian New Zealand Clinical Trials Registry 
(CTRN12606000261516). Patients for both stages of the trial have now been recruited and 
are being followed up for disease-specific outcomes. 
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Findings: The proportion of missing values at the 5%, 10% 15% and 20% differences in the 
FACT-G scale was 6% (12/190) in the TLH and 14% (20/142) in the TAH group. There were 
8/332 conversions (2.4%, 7 of which were from TLH to TAH). In the early phase of 
recovery, patients undergoing TLH reported significantly greater improvement of QoL from 
baseline compared to TAH in all subscales except the emotional and social well-being 
subscales. Improvements in QoL up to 6 months post-surgery continued to favour TLH 
except for the emotional and social well-being of the FACT  and the visual analogue scale of 
the EuroQoL five dimensions (EuroQoL-VAS).  Length of operating time was significantly 
longer in the TLH group (138±43 mins), than in the TAH group at (109±34 mins; p=0.001). 
While the proportion of intraoperative adverse events was similar between the treatment 
groups (TAH 8/142, 5.6%; TLH 14/190, 7.4%; p=0.55), postoperatively, twice as many 
patients in the TAH group experienced adverse events of  CTC grade 3+ than in the TLH 
group (33/142, 23.2% and 22/190, 11.6%, respectively; p=0.004).  Postoperative serious 
adverse events occurred more frequently in patients who had a TAH (27/142, 19.0%) than a 
TLH (15/190, 7.9%) (p=0.002). 
Interpretation: QoL improvements from baseline during early and later phases of recovery, 
and the adverse event profile significantly favour TLH compared to TAH for patients treated 
for Stage I endometrial cancer. 
 
Funding:  Cancer Council Queensland, Cancer Council New South Wales, Cancer Council 
Victoria, Cancer Council Western Australia; NHMRC project grant 456110; Cancer Australia 
project grant 631523; The Women and Infants Research Foundation, Western Australia; 
Royal Brisbane and Women’s Hospital Foundation; Wesley Research Institute; Gallipoli 
Research Foundation; Genentech; TYCO Healthcare, Australia; Johnson and Johnson 
Medical, Australia; Smart Health Research Grant QLD Health.
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Introduction 
Endometrial cancer is the most common gynaecological malignancy in developed countries 
and 80% will be diagnosed at early stages 1 or 2 (1, 2). Primary treatment of early-stage 
endometrial cancer is surgical and includes a total hysterectomy, bilateral salpingo-
oophorectomy, with or without  pelvic and aortic lymph node dissection (3). Traditionally, an 
extrafascial total abdominal hysterectomy (TAH) has been performed through a laparotomy 
in most centres worldwide (4, 5). However laparoscopic hysterectomy techniques have 
gained popularity in recent years as summarised in two systematic reviews and one meta-
analysis (6-9).  Laparoscopic Assisted Vaginal Hysterectomy (LAVH) has been associated 
with less tissue trauma, lower estimated blood loss, less pain, shorter hospital stay, and less 
time off work compared to TAH (10-15). A further potential advantage of laparoscopic 
techniques over TAH is improved quality of life (QoL) post-surgery.  A small trial comparing 
QoL following LAVH or TAH (15) found that the laparoscopic group had significantly better 
QoL values at one, three, and six months post-surgery.  In a recent Gynecologic Oncology 
Group (GOG LAP-2) trial, patients in the laparoscopy group (various laparoscopy-assisted 
procedures allowed) had superior short-term QoL outcomes compared to the TAH group up 
to six weeks post-surgery, but by six months both groups had similar QoL except for body 
image in favour of the laparoscopic procedure (16). The focus of the present study is on Total 
Laparoscopic Hysterectomy (TLH). Compared to previous laparoscopic techniques TLH 
represents a new and innovative approach, as the procedure can be completed entirely 
laparoscopically without the need for a vaginal surgical phase (17).  
To collect high quality outcome data for this new surgical procedure (18), we initiated a two-
stage international phase 3 multi-centre randomised-controlled surgical trial. The primary 
objective of stage 1 was to test the hypothesis that TLH results in equivalent or improved 
QoL up to 6 months after surgery compared to TAH. The primary objective of stage 2 was to 
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test the hypothesis that disease-free survival at 4.5 years is equivalent for TLH and TAH.  
Results addressing the primary objective of stage 1 are presented here.  
 
Methods 
The trial was initiated in 2005, registered with clinicaltrials.gov (NCT00096408) and the 
Australian New Zealand Clinical Trials Registry (CTRN12606000261516), and approved by 
all relevant hospital and university ethics committees. The protocol can be found 
http://www.gyncan.org/page/attachment/24/lace-protocol-v6-march-2009.  
Trial design: A detailed description of the study methods including details of the two surgical 
approaches has been published previously (19). In brief, we followed a two-stage clinical trial 
design. During the formal QoL substudy we randomised 361 patients into TLH versus TAH 
to assess QoL. To establish the feasibility of enrolment and to maximise the evidence for the 
new procedure, a 2:1 randomisation scheme was used for the first 180 patients, followed by 
1:1 allocation for all remaining patients. Following on from stage 1, another 575 patients 
were enrolled for a total of 755 patients (completion June 2010) randomisation.  
Eligibility criteria: Patients were recruited through one of 19 participating tertiary 
gynaecological cancer centres in Australia, New Zealand, and Hong Kong.  Women were 
eligible if they were older than 18 years, with histologically confirmed stage 1 endometrioid 
endometrial adenocarcinoma (irrespective of histological grade) and ECOG performance 
status <2. Patients had to have a CT scan of the abdomen and the pelvis suggesting the 
absence of extrauterine disease in the abdomen, and a chest X-Ray or a CT scan of the chest 
to suggest absence of pulmonary metastasis. All patients provided written informed consent. 
Patients were excluded if they met any of the following conditions: histological cell type 
other than endometrioid on curettings, clinically advanced disease (stage 2 to 4) or bulky 
7 
 
lymph nodes based on imaging, uterine size larger than 10 weeks of gestation, estimated life 
expectancy less than 6 months, medically unfit for surgery, patient compliance and 
geographic proximity not allowing adequate follow-up, or unfit to complete QoL 
assessments. The FIGO 2009 staging classification was used (20). 
Randomisation and masking: Randomisation using stratified permuted blocks was carried out 
centrally and independent from other study procedures through a web-based system at the 
University of Queensland, ascertaining concealment of the next allocated treatment to study 
staff.  During stage 1 of the trial, randomised permuted blocks were used to allocate patients 
between the two treatment groups with an allocation ratio of 2:1, favouring the intervention 
of TLH (mixed blocks of sizes 3 and 6). Randomisation was stratified according to treating 
centre and by grade of differentiation (as taken from the endometrial biopsy/D&C).   
The 2:1 randomisation was initially selected in order to gain insight into the new laparoscopic 
procedure. As a result, enrolment was above expectations and the trial was attractive for 
granting bodies offering seed funds, which allowed us to apply for substantial funding for 
stage 2 of the LACE trial evaluating the two surgical procedures in an equivalence trial 
design with respect to survival. When funding for the larger study was secured, the 
randomisation reverted to 1:1 but it was also felt that the QoL study should continue to a 
sample size of 360. After 180 patients were randomised the programme was adjusted to allow 
a 1:1 randomisation stratified according to treating centre, grade of differentiation and history 
of cancer but not to be influenced by the 2:1 imbalance in the strata.   
All surgeons on the trial had to be accredited gynaecological oncologists, had to complete at 
least 20 TLHs, had to submit video footage about a TLH, and finally had to perform a TLH 
live in the presence of a senior accredited surgeon. Surgeons discussed the study with the 
patients and obtained informed consent. Study staff then completed baseline assessments and 
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obtained the allocated treatment via the web-based case report system. Blinding was not 
possible due to ethical considerations and the nature of the treatment.  
Surgical technique: The surgical procedures have been described in detail previously (19). 
Briefly, TLH is a four-point laparoscopic procedure. A silicone tube with a diameter of 45 or 
35mm and a lid on its outer end is inserted transvaginally (McCartney Transvaginal tube®), 
and aids reflecting the bladder peritoneum, outlining the vaginal fornices, securing the uterine 
vessels laparoscopically and finally acts as a conduit to remove the specimens from the 
patient. The vaginal vault was sutured laparoscopically. 
Surgeons were required to perform pelvic ± para-aortic lymph node dissection as part of the 
treatment in both arms.  However a lymph node dissection could be omitted if any of the 
following criteria were met: morbid obesity, well-differentiated or moderately differentiated 
tumours invading only to the inner half of the myometrium, or medically unfit for lymph 
node dissection.  
Conversion from assigned treatment was noted in 8/332 cases (2.4%).  Of these, 1/332 patient 
changed from TAH to TLH after randomisation due to patient preference, while 7/332 
changed from TLH to TAH (five for anatomical reasons preventing the completion of TLH; 
one due to intra-operative complications; and one patient was found to have advanced 
disease). 
Baseline assessments were performed before randomisation (up to 28 days prior to surgery), 
collecting demographic information, height and weight, and QoL data.  Follow-up 
assessments for QoL and short-term surgical outcomes were performed at 1 week, 4 weeks, 3 
months, and 6 months post-surgery (± 3 days), to assess early (up to 4 week) and late (up to 6 
months) post-surgical recovery, respectively.   
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Quality of Life Measurements 
The primary outcome measure of QoL was the Functional Assessment of Cancer Therapy-
General (FACT-G) Version 4 questionnaire  (21). Patients raw scores on the physical (PWB) 
(7 items, range: 0-28), social (SWB) (7 items, range: 0-28), emotional (EWB) (6 items, 
range: 0-24), and functional (FWB) (7 items, range: 0-28) well-being subscales were 
measured (22). Patients also completed a 17-item endometrial subscale, which together with 
the FACT-G forms the FACT-Endometrial (EnWB).  All subscales and summary scores were 
recoded and scored according to standard  FACT scoring algorithms such that higher scores 
indicate better QoL (22).  
 
Body Image Scale 
The Body Image Scale is a ten-item scale designed for cancer patients.  The ten items were 
rated on a 0-3 scale (0 = “not at all”, 1= “a little”, 2= “quite a bit”, 3 = “very much”) and 
summed to produce an overall summary score ranging from 0 (best body image – no 
symptoms or distress) to 30 (worst body image) (23).   
 
EuroQoL five dimensions (EQ-5D)  
The EQ-5D is a simple measure of generic QoL. It allows patients to rate their overall health 
on a visual analogue scale of 1-100 (EuroQoL-VAS) (24) which was used for the present 
analysis.  
 
For ease of interpretation all QoL scales were subsequently transformed to 0-100 scales with 
higher scores indicating better QoL (25). Based on the literature a 5% difference or more in 
the QOL scores were predefined as clinically significant (26-28). Difference scores were 
calculated to assess change in QOL from baseline (pre-surgery). Forest plots (see statistical 
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analysis) were used to represent early and late recovery of QoL from baseline and assess the 
relative recovery comparing TLH to TAH treated patients, with positive values favouring 
TLH.  
Documentation of surgery details, adverse events and length of hospital stay (LOS) 
 Pre-existing surgical and medical history was taken prior to surgery. After surgery, patients 
were assessed on a daily basis by their gynaecological oncologist until discharge from 
hospital. Surgical outcomes including length of operating time, intraoperative complications, 
cross-overs (e.g., conversion to laparotomy) and reasons for conversion, were documented 
immediately following surgery. Intraoperative injuries were coded in the categories of 
visceral injury, blood transfusion, uterus rupture, vaginal laceration or vascular injury.  Post-
operative adverse events (AEs) were recorded at predefined time points up to six months 
using the NCI Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Serious 
AEs were defined as any event that resulted in death, was immediately life threatening, 
required inpatient hospitalization or prolongation of an existing hospitalization or that 
resulted in persistent or significant disability/incapacity. Length of hospital stay (LOS) was 
measured from the day after surgery (day 1) to discharge. Length of operating time was 
measured from skin incision to completion of wound closure.  
 
Statistical analysis 
Sample size: For the stage I QoL component, recruitment commenced in 2005 with a 2:1 
randomisation scheme.  For the QoL outcomes, aassuming 80% power, 10% overall non-
compliance,  a  5% type I error rate (95% confidence level) and a 2-tailed comparison, a 
sample size of at least 180 patients (120 allocated to TLH, 60 patients to TAH) was estimated 
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to detect a 10% difference (and standard deviation of 20) in the FACT-G between 
intervention and control group participants (26). However, when literature suggested a 5% 
difference in QoL to be clinically important (27-29) the collection of QoL data was extended 
to include 361 patients, (and standard deviation revised from 20 to 16.9 units). 
 
QoL over time was analysed by computing change scores between baseline measurements 
and each post-operative time point measurement. The primary endpoint for the QoL analysis 
was the difference between the groups in QoL changes from baseline.  The main analysis was 
broken into two parts, early (1 and 4 weeks) and late (3 and 6 months) for each QoL variable.  
Differences in change scores between the TAH and TLH were then compared separately for 
early and late recovery periods using Generalized Estimating Equations (GEE), with an 
exchangeable correlation structure to account for repeated measures. This method enables the 
inclusion of observations from subjects who have either dropped out or have intermittent 
missing data (30). Mean group differences between TAH  and TLH, together with the 95% 
confidence intervals (95% CI),  for each of the QoL domains were compiled, with positive 
percent differences representing an absolute advantage for the TLH group compared to TAH 
and were presented in a forest plot. Differences were considered statistically significant if the 
p-value was less than 0.05. No adjustment for multiple comparisons were made, and as such, 
the results should be viewed with some caution with special attention to the size of any 
difference, the plausible range (95% CI) of this difference together with any relevant clinical 
benefit rather than just the statistical p-value. 
FACT-G change scores were used to examine QoL improvement over time.  Early recovery 
in QoL was derived by taking the maximum improvement from weeks 1 and 4 
measurements, except where the participant had not completed measurements at both time 
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points, in which case the single available measurement was used.  The maximum 
improvement was then dichotomized in a number of different ways showing at least 5%, 
10%, 15% and 20% improvement. Contingency tables were then used to compare 
improvement for TAH and TLH, and chi square tests were used to assess difference between 
the groups. In a similar way, late recovery in QoL was derived by using the change scores at 
3 and 6 months. Missing value patterns were investigated by examining the association of 
baseline variable using univariate and multivariate logistic models to the presence of missing 
QoL outcomes for both the early and late periods (30). All comparisons between groups were 
evaluated on an intention-to-treat principle.  SAS™ statistical software, version 9.1 (31) and 
ACCoRD, version 1.68 (32) was used.  All comparisons are two-sided with a nominal 
significance level of 5%.  
Role of the funding source 
The study sponsors had no role in study design, data collection, data analysis, data 
interpretation or writing of the report. The corresponding author had full access to all of the 
data and the final responsibility to submit for publication.  
 
Results 
In total, 784 patients were screened for inclusion between October 7, 2005 and April 16, 
2008, and 361 were found eligible. Of those, 29 patients did not complete the QoL 
measurements (14 refused, 15 other reasons). Overall, 332 patients were included in the QoL 
component, 142 in the TAH group, and 190 in the TLH group (Figure 1).  Patients 
randomised to TAH or TLH had similar demographic characteristics but patients assigned to 
TAH had better QoL at baseline (although most confidence intervals overlapped) (Table 1). 
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Patients treatment characteristic are reported in Table 2. Patients who had a TLH were less 
likely to have received a lymph node dissection for surgical staging purposes (Table 2). A 
significantly higher proportion of patients who were assigned to TAH stayed in hospital for 2 
days or more (139/142 after TAH compared to 72/190 after TLH, p<0.0001). The median 
(IQR) time to surgery was 7 (4-13) days for TAH and 7 (4-13) days for TLH (p= 0.90). 
Quality of Life recovery  
Figure 2 presents the mean values and 95% confidence intervals for patients randomised to 
the TAH and TLH groups at predetermined time points. For the domains measuring PWB, 
FWB, EnWB, FACT-G, EuroQol-VAS and body image scale there was a decrease in QoL 
one week post surgery with a gradual QoL recovery up to six months. This is not unexpected 
and may reflect the trauma of the surgical intervention. EWB and SWB showed a gradual 
QoL recovery where at baseline these scores reflect low (poor QoL) values prior to surgery, 
followed by an improvement once the threat of cancer had been removed. 
Figure 3 presents the change in QoL scores from baseline, comparing early and late recovery 
among patients who received TLH to those who received TAH (forest plot). For ease of 
comparison, the scores have been rescaled on a 0-100 point scale and benefits can be 
interpreted as a percentage benefit/detriment. In early recovery (up to 4 weeks post surgery), 
patients with TLH experienced a clinically and statistically significantly greater improvement 
in most QoL measurements, compared to patients receiving TAH. The greatest differences 
were noted in functional well-being (13% greater improvement for patients with TLH), 
followed by physical well-being (11% greater), endometrial cancer-specific well-being (6% 
greater) and overall FACT-G summary score (7% greater) (p=0.001 for all comparisons). 
Patients with TLH also reported 5% (p=0.001) greater improvements in their body image and 
7.5% (p=0.001) in overall QoL (EQ-VAS) compared to patients with TAH. There was no 
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significant difference during early recovery in emotional (p=0.39) or social wellbeing 
(p=0.59) between patients assigned TAH or TLH. During the late post-operative recovery 
phase (3 to 6 months post surgery), patients with TLH compared to patients with TAH 
recovered significantly more in their physical (p=0.008), functional (p=0.009), endometrial 
cancer-specific (p=0.003), and overall well-being (FACT-G) (p = 0.03), and also experienced 
superior QoL recovery with regards to body image (p=0.001).  
There was an imbalance in the number of lymph node dissections (LND) performed between 
the two treatments. Patients who received LND had significantly lower QoL in FWB and 
FACT-G at early recovery (1 to 4 weeks postoperatively) compared to those without LND. 
QoL was not different in all other subscales and in any subscales at late recovery (3 to 6 
months postoperatively). LND was significantly related to FACT-G (p=0.01) and FWB 
(p=0.04) at early recovery, with treatment remaining highly significant in favour of TLH 
even after adjustment for LND. For all other subscales and all subscales at late recovery there 
was no significant interaction between LND and treatment allocation.  
While the QoL scales provide for changes on a continuous scale, of clinical value is a 
comparison by treatment of those patients who benefited by a threshold amount. The 
proportion of women who experienced an improvement in QoL by 5% or more, as measured 
by the FACT-G, was significantly greater among patients assigned to TLH compared to TAH 
in both the early (51% (92/179) TLH compared to 29% (36/122)  TAH, p <0.0001) and late 
(69% (121/175) TLH compared to 58% (67/116) TAH, p =0.04) post-operative recovery 
period (Table 3). This table also shows that the improvement in the FACT-G is maintained as 
the clinical threshold is increased and is maintained at the late recovery period.  
The number of women with completely missing QoL assessments was low, from 8/332 
(2.4%) at baseline increasing to 42/332 (12.7%) at six months post-surgery. Overall, 263/332 
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(79.2%) of participants provided data at all five time points, and a further 30/332 (9%) 
completed measures at all but one timepoint. A higher proportion of patients assigned to 
TAH compared to TLH did not complete any QoL forms at 1 week (12/142 (8.5%) versus 
4/190 (2.1%), and 6 months (24/142 (16.9%) versus 18/190 (9.5%), post surgery. 
The proportion of missing values data at the 5%, 10% 15% and 20% differences in the 
FACT-G scale was 6% (12/190)  in the TLH and 14% (20/142) in the TAH group. This 
imbalance was investigated further to determine whether there was any signal of a systematic 
pattern in the missing values during the early and late periods, we examined the association 
of the baseline variables: Age, obesity, grade, ECOG, lymph node dissection and whether 
there was a correlation with the FACT-G changes being missing. No such patterns were 
found in either the early or late missing periods in a univariate or multivariate logistic 
analysis, other than a treatment imbalance. There was no significant interaction between 
treatment and these variables on whether the response was missing suggesting that any 
systematic pattern which could be present would be well within the play of chance. The 
missing data patterns for the other outcomes were similar (i.e. no discernable trend). 
Surgical and short term outcomes 
Length of operating time was significantly longer in the TLH group (138±43 mins), than in 
the TAH group at (109±34 mins; p=0.001). There was no significant difference in numbers of 
patients with intraoperative adverse events between the TLH (14/190,7.4%) and TAH 
(8/142,5.6%) groups (p = 0.55).  Two patients had an SAE intraoperatively (one TLH, one 
TAH).  The first patient experienced an inadvertent cystostomy at TLH, resulting in 
prolonged hospitalisation.  The second patient, in the TAH group, had a rotten tooth knocked 
out during intubation, causing oropharyngeal bleeding resulting in a difficult endotracheal 
intubation.  This patient was transferred to the Intensive Care Unit postoperatively for 
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monitoring. Postoperatively, more than twice as many patients in the TAH group experienced 
AEs CTC grade 3+ than in the TLH group (33/142, 23.2% and 22/190, 11.6% respectively; 
p=0.004).  Postoperative serious AEs occurred more frequently in patients who had a TAH 
(27/142, 19.0%) than a TLH (15/190, 7.9%) (p=0.002). Specific complications are presented 
in Table 4.  No treatment-related patient deaths were recorded.  
The mean haemoglobin decline from pre-surgery to first day post-surgery was 1.8±1.1 g/dL 
in the TLH group and 2.1±1.1 g/dL in the TAH group (p = 0.013).  A larger proportion of 
patients stayed at hospital post-surgery for 2 days or more after TAH (139/141, 98.6%) 
compared to patients after TLH (72/191, 37.7%) (p<0.0001). 
 
Discussion 
QoL improvements from baseline during early and later phases of recovery, and the adverse 
event profile significantly favour TLH compared to TAH for patients treated for Stage I 
endometrial cancer.QoL was measured on a variety of validated subscales.  Patients treated 
with TLH had significantly greater improvements in QoL from pre-surgery levels at both, 
early (up to four weeks) and late post-operative recovery (up to 6 months) compared to 
patients treated by TAH.  Differences in subscale scores reflected superior physical, 
functional and overall QoL as well as body image in the TLH group, while social and 
emotional components of QoL remained largely stable across post-surgery time-points and 
between groups. Better physical and functional well-being reflects our clinical experience 
that patients who had a TLH return to normal activities more quickly, which seems especially 
relevant given the ageing of the population (33). A larger proportion of patients treated with 
TLH had improvements of 5% or more from baseline QoL during the early and late recovery 
after surgery for endometrial cancer. 
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To date, two prospective clinical trials compared QoL following laparoscopic and open 
surgery using a validated self-reported QoL scale, although neither studied TLH specifically 
(15, 16).  An Italian trial randomised 84 patients comparing LAVH with TAH  and found that 
patients treated with LAVH had significantly better overall QoL at four weeks,  three and six 
months post-surgery, compared to patients treated with open surgery (15), which is similar to 
the more prolonged improvement of QoL found in the current study.  The Gynecologic 
Oncology Group (GOG) LAP-2 trial randomly assigned patients to either open or 
laparoscopic (LAVH or TLH) treatment (n=802).  As in the current trial, the FACT scale was 
used as the primary measure of QoL.  Completion rates of QoL questionnaires were similar. 
Patients in the laparoscopic group had superior QoL compared to the open surgery group up 
to six weeks postoperatively but QoL scores were similar between the laparoscopic and the 
open arm at 6 months (16, 34).     
A persistent QoL difference in the LACE trial favouring TLH at six months was thus maybe 
unexpected and may be due to a number of reasons. In the LAP-2 trial 25.8% of patients were 
converted from laparoscopic to open surgery and those patients had the lowest QoL at all but 
one time point, compared to successful open or laparoscopy patients. While both trials 
required surgeons’ accreditation, the LAP-2 trial required a full pelvic and aortic lymph node 
dissection in all patients regardless of pre- or intraoperative findings. The need for a full 
pelvic and aortic node dissection was the most common reason for conversion to laparotomy 
in LAP-2. In the LACE trial, surgeons were also required to perform pelvic ± para-aortic 
lymph node dissection as part of the treatment in both arms but they could elect to omit a 
lymph node dissection if patients met specific criteria as outlined above. In LACE, 52% of 
patients had a pelvic and/or aortic lymph node dissection, which is comparable with previous 
reports (35).  However, a lower proportion of patients receiving TLH than TAH underwent a 
lymph node dissection, which may have contributed to better QoL outcomes in the 
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laparoscopic group in the early phase of surgical recovery. Indeed, when we assessed the 
effect of lymph node dissection on QoL outcomes adjusted for treatment received, LND only 
influenced FACT-G and FWB at early recovery.   
Another reason for the good QoL results in the TLH group could be that the LACE trial 
started enrolment later than the LAP-2 trial and the trial management committee made an 
enormous effort to ascertain that all surgeons were beyond their individual learning curve. All 
surgeons had to complete 20 unsupervised TLH procedures, had to submit video footage of 
one procedure, which qualified them to perform a live TLH and node dissection, which was 
witnessed by one of the senior LACE trial surgeons attending in person. Comparing QoL 
scores from early enrolment to QoL scores from late enrolment found no differences (data not 
shown). One further explanation for the QoL differences between LACE and LAP-2 could 
also be that no LAVH was performed in the LACE trial, and all procedures were completed 
totally laparoscopically, whereas the majority of procedures were LAVH in the LAP-2 trial 
(36).  
Last but not least, the statistical analysis model differed between the two RCTs. In LACE, we 
compared individual QoL differences for each patient between baseline and early (up to 3 
months) and late (up to 6 months) after surgery in the TLH and the TAH group. In contrast, 
adjusted mean QoL values were compared for the laparoscopic and the open group and 
compared within the specified time points (1, 3, 6 weeks and 6 months) in the LAP-2 trial. 
Therefore, our statistical analysis approach is not influenced by statistically significant 
differences in QoL values at baseline as seen in the subscale “physical functioning” in the 
LAP-2 trial (16).  
Past prospective studies have indicated that the laparoscopic approach is comparable to or 
better than the abdominal approach in terms of short-term outcomes such as complications, 
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blood loss, and length of hospital stay (6, 8, 36).  TLH specifically has been shown to be 
advantageous for these outcomes in retrospective series (17, 37) and this has been confirmed 
in the present analysis, with a smaller proportion of patients randomised to TLH experiencing 
post-operative adverse events.  Quicker recovery from surgery and freedom from post-
operative adverse events will thus likely have contributed to better QoL outcomes in patients 
with TLH. 
Limitations of our study include those frequently encountered by surgical trials. Blinding of 
patients and treatment team has not been attempted. Randomisation was well ahead of 
surgery and for ethical reasons patients had to be aware of the treatment they were to receive. 
Recruitment for the study was conducted in hospitals well equipped to deal with patients after 
major abdominal surgery and the new laparoscopic technique.  
In summary, the results of this randomised-controlled trial demonstrate that QoL recovery in 
endometrial cancer patients undergoing surgery by TLH is clinically and statistically 
significantly superior during the early and late post-operative phases, compared to QoL in 
those treated with TAH. The QoL findings are more pronounced than those of some earlier 
trials, most likely because the conversion rate from TLH to TAH was very low. Further 
follow-up of the patients in this trial will ascertain the equivalence of disease-free survival. 
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Table 1. Patient characteristics (by treatment group)** 
Characteristic Total 
332 (%) 
TAH 
142 (%) 
TLH 
190 (%) 
Age 
mean 
Standard deviation 
   
62.8 62.7 62.8 
9.9 9.7 10.0 
BMI category*    
Normal (18.50-24.99) 45 (14.4) 21 (15.6) 24 (13.6) 
Overweight (25.00-29.99) 70 (22.4) 26 (19.3) 44 (24.9) 
Obesity Class I (30.00-34.99) 76 (24.4) 39 (28.9) 37 (20.9) 
Obesity Class II (35.00-39.99) 54 (17.3) 23 (17.0) 31 (17.5) 
Obesity Class III (≥40) 67 (21.5) 26 (19.3) 41 (23.2) 
Education    
Completed 12 years of schooling or less 230 (75.2) 94 (74.6) 136 (75.6) 
Completed >12 years of schooling  76 (24.8) 32 (25.4) 44 (24.4) 
Employment    
Retired 135 (44.1) 51 (40.5) 84 (46.7) 
Employed full-time 38 (12.4) 18 (14.3) 20 (11.1) 
Employed part-time or casual 41 (13.4) 20 (15.9) 21 (11.7) 
Other 92 (30.1) 37 (29.4) 55 (30.6) 
Marital Status    
Married/living together 206 (67.3) 85 (67.5) 121 (67.2) 
Other 100 (32.7) 41 (32.5) 59 (32.8) 
Private health insurance    
Yes 219 (28.4) 41 (32.5) 46 (25.6) 
No 87 (28.4) 85 (67.5) 134 (74.4) 
Income    
Less than $40,000 201 (65.7) 76 (60.3) 125 (69.4) 
$40,000+ 64 (20.9) 31 (24.6) 33 (18.3) 
Not answered 41 (13.4) 19 (15.1) 22 (12.2) 
Birth Country    
Australia 212 (69.3) 88 (69.8) 124 (68.9) 
Other 94 (30.7) 38 (20.2) 56 (31.1) 
ECOG Performance Status    
0  282 (84.9) 122 (85.9) 160 (84.2) 
1  50 (15.1) 20 (14.1) 30 (15.8) 
Quality of life at baseline Mean (95% CI) Mean (95% CI) Mean (95% CI) 
PWB   85.1 (83.2,87.1) 87.6 (85.0,90.2) 83.4 (80.7,86.1) 
SWB 82.7 (80.8,84.6) 83.0 (80.0,86.0) 82.5 (80.0,85.0) 
EWB 73.7 (71.4,75.2) 74.6 (71.1,78.0) 73.0 (70.1,76.0) 
FWB 74.6 (72.3,76.9) 78.2 (75.0,81.5) 71.9 (68.8, 75.1) 
ENWB 81.0 (79.3, 82.7) 83.3 (80.9,85.7) 79.3 (77.0,81.6) 
FACT-G 79.7 (78.2,81.2) 81.7 (79.5,83.8) 78.4 (76.4,80.3) 
Body image scale 88.5 (86.6, 90.4) 91.4 (89.1,93.8) 86.4 (83.8,89.1) 
EuroQOLVas 77.8 (75.8,79.9) 78.5 (75.1,81.8) 77.4 (74.7,80.1) 
*Based on WHO categories, **n do not always add to 332 due to missing demographic data; Abbreviations: 
PWB=physical well -being; SWB=social well-being; EWB=emotional well-being; FWB=functional-well being; 
ENWB=endometrial well-being; FACTG= Functional Assessment of Cancer Therapy-General; 
EuroQoLVas=Visual analogue scale or the EQ -5D.
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Table 2. Clinical characteristics (by treatment group) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**Found to have cervical cancer 
Characteristic Total 
332 (%) 
TAH 
142 (%) 
TLH 
190 (%) 
Grade of Differentiation    
Grade 1 – Well differentiated 211 (63.6) 89 (62.7) 122 (64.2) 
Grade 2 – Moderately differentiated 105 (31.6) 46 (32.4) 59 (31.1) 
Grade 3 – Poorly differentiated  16 (4.8) 7 (4.9) 9 (4.7) 
Surgical Stage    
IA 246 (74.1) 104 (73.2) 142 (74.7) 
IB 34 (10.2) 13 (9.2) 21 (11.1) 
II 30 (9.0) 16 (11.3) 14 (7.4) 
IIIA 6 (1.8) 1 (0.7) 5 (2.6) 
IIIB 1 (0.3) - 1 (0.5) 
IIIC1 5 (1.5) 3 (2.1) 2 (1.1) 
IIIC2 6 (1.8) 3 (2.1) 3 (1.6) 
IVB 1 (0.3) 1 (0.7) - 
Other** 3 (0.9) 1 (0.7) 2 (1.1) 
Node dissection performed    
No 159 (47.9) 46 (32.4) 113 (59.5) 
Yes 173 (52.1) 96 (67.6) 77 (40.5) 
Tumour Types    
Endometroid adeno-carcinoma 309 (93.1) 132 (92.9) 177 (93.2) 
other 23 (6.9) 10 (7.1) 13 (6.8) 
Adjuvant therapy    
none 263 (79.2) 111 (78.2) 152 (80.0) 
Chemotherapy and/or radiation 69 (20.8) 31 (21.8) 38 (20.0) 
Hospital stay    
≤2 days 121 (36.4)    3 (2.1) 118 (62.1) 
>2 days 211 (63.6) 139 (97.9) 72 (37.9) 
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Table 3. Proportion of women whose quality of life (FACT-G) improved by at least 5, 10, 15 or 20% 
from baseline during the early and later recovery period 
 
 
   FACT-G improvement  
 5% p-value 
95% CI* 
10% p-value 
95% CI* 
15% p-value 
 95% CI* 
20% p-value  
95% CI* 
Early (up to 4 weeks)  
TLH 
n=179 
92 
51% 
 
<0.0001 
(11%, 33%) 
55 
31% 
 
0.001 
(8%,26%) 
32 
18% 
 
.001 
(7%, 20%) 
19 
11% 
 
0.01 
(3%, 13%) TAH 
n=121 
36 
29% 
17 
14% 
5 
4% 
3 
2% 
Late (up to 6 months)  
TLH 
n=175 
121 
69% 0.04 
(0.1%, 23% 
85 
49% 
 
0.02 
(3%,25% 
46 
26% 
 
0.27 
(-4%, 15% 
25 
14% 
 
0.74 
(-7%, 9%) TAH 
n=116 
67 
58% 
40 
34% 
24 
21% 
15 
13% 
*95% confidence interval for the difference in proportions showing an improvement between the 
TAH and TLH groups
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Table 4. Intra and post-operative adverse events in TAH and TLH groups  
 
Adverse Events (n, %) Total  
(n=332) 
TAH  
(n=142) 
TLH  
(n=190) 
p-value 
Intraoperative     
Any 22 (6.6) 8 (5.6) 14 (7.4) 0.549 
Visceral injury 9 (2.7) 3 (2.1) 6 (3.1)  
Blood transfusion 3 (0.9) 3 (2.1) -  
Uterus rupture 1 (0.5) - 1 (0.5)  
Vaginal laceration 6 (1.8) - 6 (3.1)  
Vascular injury 3 (0.9) 2 (1.4) 1 (0.5)  
Postoperative*     
Any 55 (16.6) 33 (23.4) 22 (11.5) 0.004 
Wound infection 15 (4.5) 13 (9.2) 2 (1.0)  
Cardiac general 10 (3.0) 4 (2.8) 6 (3.1)  
Pulmonary/upper respiratory 9 (2.7) 4 (2.8) 5 (2.6)  
Gastrointestinal 7 (2.1) 5 (3.5) 2 (1.0)  
Wound dehiscence 6 (1.8) 6 (4.3) -  
Hemorrhage/bleeding 5 (1.5) 3 (2.1) 2 (1.0)  
Blood/bone marrow 4 (1.2) 4 (2.8) -  
Others** 4 (1.2) 2 (1.4) 2 (1.0)  
Renal/genitourinary 4 (1.2) 2 (1.4) 2 (1.0)  
Constitutional symptoms 3 (0.9) 1 (0.7) 2 (1.0)  
Metabolic/laboratory 3 (0.9) 3 (2.1) -  
Neurology 3 (0.9) - 3 (1.6)  
Vascular 3 (0.9) 2 (1.4) 1 (0.5)  
Cardiac arrhythmia 2 (0.6) 1 (0.7) 1 (0.5)  
Infection 2 (0.6) - 2 (1.0)  
Musculoskeletal/soft tissue 2 (0.6) 1 (0.7) 1 (0.5)  
Lymphatics 1 (0.3) - 1 (0.5)  
Pain 1 (0.3) 1 (0.7) -  
Serious Adverse Events     
Any 42 (12.7) 27 (19.1) 15 (7.9) 0.002 
Infection 19 (5.7) 14 (9.9) 5 (2.6)  
Haemorrhage/Bleeding 6 (1.8) 4 (2.8) 2 (1.0)  
Cardiac general 5 (1.5) 1 (0.7) 4 (2.1)  
Wound dehiscence 4 (1.2) 4 (2.8) -  
Cardiac arrhythmia 4 (1.2) 3 (2.1) 1 (0.5)  
Pulmonary/Upper respiratory 2 (0.6) 1 (0.7) 1 (0.5)  
Blood/Bone Marrow 2 (0.6) 2 (1.4) -  
Other*** 3 (0.9) 1 (0.7) 2 (1.0)  
 
    
* CTC grade ≥ 3; ** include extended hospital stay, difficult intubation and return to theatre in the same admission  
*** extended hospital stay, small bowel obstruction, thrombus, post anaesthesia difficulties  
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Figure 1. CONSORT diagram 
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Figure 2. Quality of life scores over time (raw mean scores and confidence intervals on 0-100 scale, 
with 0 representing  low quality of life and 100 representing high quality of life) 
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Figure 3. Forest plot of mean difference (95% CI) in QoL improvement from baseline between TLH 
and TAH groups 
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